Wells Fargo analyst Stephen Baxter lowered the firm’s price target on UnitedHealth (UNH) to $370 from $400 and keeps an Overweight rating on the shares. Beyond the disappointing MA rate, results in Optum Health and relatively low visibility into 2026 guidance for that segment were the key issues for the firm leaving Q4 2025 results. Wells is lowering estimates to refine MA and Medicaid views in 2027.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNH:
- UnitedHealth price target lowered to $327 from $391 at Barclays
- Here’s Why TD Cowen Lowered its UnitedHealth Stock (UNH) Price Target
- UnitedHealth Stock Forecast: Analysts Split As Turnaround Unfolds
- Mixed options sentiment in UnitedHealth with shares up 3.66%
- UnitedHealth price target lowered to $361 from $408 at RBC Capital